These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 25901074)

  • 1. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 2. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 3. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Tran H; Joseph J; Young L; McRae S; Curnow J; Nandurkar H; Wood P; McLintock C
    Intern Med J; 2014 Jun; 44(6):525-36. PubMed ID: 24946813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

  • 5. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anticoagulant therapy in stroke patients].
    Kraglund KL; Husted SE; Modrau B; Grove EL
    Ugeskr Laeger; 2013 Jan; 175(5):265-8. PubMed ID: 23369327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in atrial fibrillation.
    Noll G; Noll S; Hürlimann D
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 18. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.